PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Research Embryo Creation”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 73 records · Page 4Linked to original sources
PubMed2001

Cloning for therapeutic purposes: ethical and policy considerations.

This essay reviews how cloning techniques may be used for therapeutic purposes, analyzes ethical implications, and makes recommendations for public policy discourse. Although cloning may bring many potential benefits, they remain uncertain. Furthermore, human embryo research is morally problematic. Therefore, alternatives to human cloning for therapeutic aims should be sought at present. In addition to central ethical issues, public discourse should maintain an emphasis on the value of the human embryo over scientific expediency, the relativity of health, and the principle of justice. Society should support the laudable mission of medical research, while also attending to the moral concerns often threatened by the promises of scientific progress.

Catholicism↗
PubMed2001

Lengthening the stem: allowing federally funded researchers to derive human pluripotent stem cells from embryos.

Recent developments in fetal tissue research and stem cell research have led to dramatic breakthroughs in the search for cures for Parkinson's disease, Alzheimer's disease, diabetes, and a host of neurological disorders. Because this research involves fetal tissue and stem cells from human embryos, many complicated ethical and legal implications surround it. This Note explores the history of fetal tissue research and stem cell research, examines the surrounding ethical and legal issues, looks at the current state of federal law, and concludes that Congress should allow federally funded researchers to derive stem cells from discarded human embryos obtained from in vitro fertilization clinics.

Aborted Fetus↗
PubMedDate not supplied

Cloning human beings. Responding to the National Bioethics Advisory Commission's Report.

In February of this year two figures were added to our daily life. Dolly, a cloned sheep, and her maker, Scottish scientist Ian Wilmut, could be found in our newspapers, on our televisions, across the Internet, and in our conversations. What Wilmut had done was indeed new, if not fantastic. By transferring the nucleus of a somatic cell from an adult animal into an egg from which the nucleus had been removed, Wilmut successfully cloned a mammal--a technique that had never before succeeded.

Advisory Committees↗
PubMed2002

Human embryonic stem cell lines: the ethics of derivation.

In Canada it is permissible to proceed with stem cell research using human embryos created by in vitro fertilization (IVF) provided: these were originally created for infertility treatment; they are no longer required for such treatment; and there is an appropriate consent for their research use. As such, IVF human embryos in excess of clinical need are a valuable resource for embryonic stem cell researchers. A point often overlooked, however, is that these excess IVF human embryos are also a scarce resource. Their scarcity suggests the need to develop sound policies and procedures, in a timely and coordinated fashion, to ensure that the few human embryos available for embryonic stem cell research are not used in less important research endeavours or used when other biological materials are appropriate. Injudicious use of the few human embryos available for research use may risk the following consequences: no ongoing research in Canada to derive human embryonic stem cell lines; a reliance on the importation of stem cell lines from other countries for any research on the use of embryonic stem cells; and pressure from Canadian researchers to remove the prohibition on the purposeful creation of human embryos for research use.

Canada↗
PubMed1996

Washington politics and genetic engineering research: when worlds collide.

In earlier research, I developed a notion of "biopolitics" to help explain, first, the recombinant DNA debate of the 1970-1980s, and, second, the human gene transfer-therapy debate of the 1980-1990s. Drawing upon results gleaned from two recent meetings of high moment in the nation's capital, I expand upon the theoretical and empirical parameters of the biopolitical argument to elucidate the clash of policy preferences arising from two new areas of genetic experimentation: (i) human embryo research and (ii) the creation of commercially viable therapeutics to combat disease. I show the manner in which members of the biological science community and their policy allies are forced to cope with the realities of the "Washington political game," and why it is necessary for them to develop a sophisticated sense of what that "game" is.

Advisory Committees↗